Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103545
Status:
COMPLETED
Last Update Posted:
2006-10-02
First Post:
2005-02-10
Brief Title:
Use of ACA 125 in Patients With Ovarian Cancer Safety and Immune Response
Sponsor:
AGO Study Group
Organization:
AGO Study Group
Study Overview
Official Title:
A Phase III Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian Fallopian Tube or Peritoneal Cancer
Status:
COMPLETED
Status Verified Date:
2006-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to use an immunologic approach following the treatment for recurrent disease in patients with ovarian fallopian tube or peritoneal cancer
Detailed Description:
Patients with epithelial ovarian fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinumtaxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70 will eventually relapse Many patients respond to additional cytotoxic treatment with partial or complete responses yet approximately 100 of these patients will ultimately progress Novel consolidation strategies following treatment for recurrent disease are needed and an immunologic approach is an attractive option
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None